The Phase 1/2 clinical trial of AVB-500 is being done in combination with durvalumab in patients with ovarian cancer.
Aravive (NASDAQ:ARAV) and AstraZeneca (NYSE:AZN) have announced that a Phase 1/2 clinical trial of AVB-500 study in combination with durvalumab, in patients with recurrent epithelial ovarian cancer has begun and is recruiting patients.
As quoted in the press release:
The clinical trial is jointly funded by Aravive and AstraZeneca.
“GAS6/AXL signaling plays a key role in immune evasion, suggesting that inhibition of this pathway has the potential to augment the anti-tumor effects of an anti-PD-L1 agent to achieve better outcomes for patients,” said Gail McIntyre, Ph.D., chief scientific officer of Aravive. “Consequently, we believe there is a strong mechanistic and clinical rationale for exploring the potential of AVB-500 in combination with a checkpoint inhibitor in the treatment of ovarian cancer.”
This open-label trial will begin with a Phase 1b safety lead-in phase to determine the recommended Phase 2 dose (RP2D) for the combination of AVB-500 and durvalumab. In the Phase 2 portion, eligible subjects will participate in a 6-week monotherapy cycle randomized to either AVB-500 or durvalumab before receiving the combination therapy at the RP2D. Patients will receive treatment until progression or unacceptable toxicity with combination therapy. The study is listed on clinicaltrials.gov NCT04019288.
“There is a significant need for effective treatments that don’t add to the treatment burden for women with ovarian cancer,” said Laura Bonifacio, Pharm.D., Ph.D., vice president of clinical operations at Aravive.
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1827.54 | +0.47 | |
Silver | 21.15 | +0.03 | |
Copper | 3.74 | 0.00 | |
Palladium | 1879.51 | +6.50 | |
Platinum | 911.26 | +4.32 | |
Oil | 107.06 | +2.79 | |
Heating Oil | 4.24 | +0.02 | |
Natural Gas | 6.17 | -0.07 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.